I bet Nestle wishes it could go back and experience that “Great Shutdown” fueled demand spike again (because it went by too fast), but allowing some VMS brands to leave the nest could be its next step towards finding new growth! Within the prepared remarks section, Nestle leadership noted during the first-half 2025 earnings call that it had launched a review of its underperforming vitamins, minerals, supplements (VMS) portfolio…and that it could lead to the divestment of some brands. But wait…wasn’t it just four short years ago when Nestle completed the $5.75 billion acquisition of The Bountiful Company? Yep! Nevertheless, I'll replay a contextually relevant portion of my conversation with Teddie Townsend (Managing Director - CG Sawaya Partners) from last year that will help you better understand what’s really going on inside Nestle (and the entire supplement industry M&A strategic acquirer landscape). But when we recorded that conversational content, it wasn’t publicly known yet that Nestle would be making a leadership change…with the new CEO (i,e. Laurent Freixe) taking over in September 2024. And it meant a shift in companywide strategy naturally happened…accompanied by a clear action plan to drive performance and transformation. Additionally, the Nestle Virtuous Circle strategic framework included an element about addressing underperformers to support growth…and specifically sharpening focus within Nestle Health Science. With a diverse portfolio of brands across VMS, Active Nutrition, and Medical Nutrition…Nestle Health Science has built a leading position, and the segment generates slightly less than $8.5 billion in revenue annually. And while Nestle still believes VMS is an attractive category with clear growth drivers…new leadership is focused on the premium end of the market, which is deemed to have the highest potential. So, going forward…Nestle Health Science will focus on its global premium VMS brands such as Garden of Life, Solgar, and Pure Encapsulations, as Nestle believes its capabilities in science, innovation, and brand-building give it a distinct competitive edge. Alternatively, Nestle launched a strategic review of its mainstream and value VMS brands, including (but not limited to) Nature’s Bounty, Osteo-Bi Flex, Puritan’s Pride, and private label. And though this likely divestment activity is consistent with the “focus and simplification” strategic growth approach of Nestle’s new leadership…it basically dismantles a substantial portion of The Bountiful Company acquisition, which arguably was considered one of the predecessor’s (i.e. Mark Schneider) most substantial moves throughout his 7-year pursuit of transforming the company into a health and nutrition powerhouse. But then…for the final portion of my latest first principles content piece, I'll explore two different “what’s next” scenarios; who likely acquires these Nestle Health Science VMS brands under review and where I believe Nestle Health Science will strategically focus after the proverbial divestment dust settles.